When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – The addition of bevacizumab to adjuvant chemotherapy does not improve invasive disease-free rates in women after resection of breast cancer that’s negative for…
By Will Boggs, MD NEW YORK (Reuters Health) – Patients with unresectable primary spinal sarcoma may benefit from carbon ion radiotherapy (CIRT), Japanese researchers say. Compared with proton…
NEW YORK (Reuters Health) – Bevacizumab appears to be most effective for metastatic colorectal cancer when the primary tumor originates distally, according to a Danish study. However, the…
NEW YORK (Reuters Health) – Recurrence after limited lung resection for small early-stage adenocarcinoma is three times more likely when the micropapillary component of the tumor is 5%…
NEW YORK (Reuters Health) – The addition of aprepitant to anti-emesis treatment seems to reduce the occurrence of nausea and vomiting among patients who are likely to experience…
NEW YORK (Reuters Health) – An increase in clonal complexity precedes the transformation of smoldering myeloma to malignant multiple myeloma, researchers have shown. “As such,” they infer, “the…
NEW YORK (Reuters Health) – A score based on four factors – low albumin, high bilirubin and α-fetoprotein, and large tumor size – is closely associated with mortality…
NEW YORK (Reuters Health) – In a phase III, multinational study of patients with heavily pretreated metastatic breast cancer, adding sunitinib to capecitabine provided no benefit, and in…
NEW YORK (Reuters Health) – The results of a phase III Italian study indicate that the risk of breast cancer in postmenopausal women who use hormone replacement therapy…
By Genevra Pittman NEW YORK (Reuters Health) – Men treated for prostate cancer with androgen deprivation therapy have a higher risk of developing kidney problems, a new study…
